Drug Trial Radar · NCT04209855
A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression
Last checked: Nov 20, 2026Latest source record: Aug 27, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
453
Actual
Start
Dec 31, 2019
Primary completion
Mar 6, 2023
Study completion Oct 29, 2024
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- Collaborators
- Gynecologic Oncology Group; European Network of Gynaecological Oncological Trial Groups (ENGOT)
- First posted
- Dec 24, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase 3 study is designed to compare the efficacy and safety of mirvetuximab soravtansine (MIRV) vs. IC chemotherapy in participants with platinum-resistant high-grade epithelial ovarian cancer, primary peritoneal, or fallopian tube cancer, whose tumors express a high-level of FRα. Participants will be, in the opinion of the Investigator, appropriate for single-agent therapy for their next line of therapy. The FRα positivity will be defined by the Ventana FOLR1 (FOLR1-2.1) CDx assay.
Conditions
- Epithelial Ovarian Cancer
- Peritoneal Cancer
- Fallopian Tube Cancer
Interventions
Mirvetuximab SoravtansineDrug
Mirvetuximab Soravtansine will be administered per dose and schedule specified in the arm.
PaclitaxelDrug
Paclitaxel will be administered per dose and schedule specified in the arm.
TopotecanDrug
Topotecan will be administered per dose and schedule specified in the arm.
Pegylated liposomal doxorubicinDrug
Pegylated liposomal doxorubicin will be administered per dose and schedule specified in the arm.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free Survival (PFS) as Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1Time frame: From randomization until PD or death, whichever occurred first (up to approximately 36 months)
Locations
214 sites in 21 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham (UAB) GYN Oncology
Birmingham, Alabama
Alaska Women's Cancer Care
Anchorage, Alaska
Arizona Oncology Associates, PC - HAL - USOR
Phoenix, Arizona
Mayo Clinic
Phoenix, Arizona
USOR: Arizona Oncology Associates, PC - HOPE
Tucson, Arizona
University of Arizona Cancer Center
Tucson, Arizona
UCLA - JCCC Dept of OBGYN - Women's Health Clinical Research Unit
Los Angeles, California
Hoag Cancer Center
Newport Beach, California
University of California San Francisco
San Francisco, California
Olive View - UCLA Medical Center
Sylmar, California
Kaiser Permanente Oncology Clinical Trials
Vallejo, California
USOR: Rocky Mountain Cancer Centers
Lakewood, Colorado
Yale University School of Medicine
New Haven, Connecticut
Florida Cancer Specialist South Division
Fort Myers, Florida
Mayo Clinic Jacksonville
Jacksonville, Florida
Sarasota Memorial Hospital
Sarasota, Florida
Women's Care Florida / Women's Cancer Associates
St. Petersburg, Florida
Florida Cancer Specialist North Division
St. Petersburg, Florida
Florida Cancer Specialists
Tallahassee, Florida
Florida Cancer Specialist East Division
West Palm Beach, Florida
Memorial University Medical Center
Savannah, Georgia
Hawaii Pacific Health - Kapiolani Medical Center for Women and Children
Honolulu, Hawaii
Illinois Cancer Specialists
Arlington Heights, Illinois
University of Chicago
Chicago, Illinois
Dr. Sudarshan K. Sharma, Ltd.
Hinsdale, Illinois
Community Health Network
Indianapolis, Indiana
University of Kansas Cancer Center
Westwood, Kansas
St. Elizabeth Healthcare
Edgewood, Kentucky
Norton Cancer Institute
Louisville, Kentucky
Ochnser Medical Center Jefferson
New Orleans, Louisiana
WK Physicians Network/Gynecologic Oncology Associates
Shreveport, Louisiana
Holy Cross Hospital
Silver Spring, Maryland
USOR: Maryland Oncology Hematology, P.A.
Silver Spring, Maryland
Tufts Medical Center
Boston, Massachusetts
Baystate Medical Center
Springfield, Massachusetts
University of Massachusetts
Worcester, Massachusetts
St. Joseph Mercy Hospital
Ann Arbor, Michigan
Karmanos Cancer Institute
Detroit, Michigan
Mayo Clinic Rochester
Rochester, Minnesota
USOR: Minnesota Oncology Hematology, PA
Woodbury, Minnesota
Showing 40 of 214 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.